FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Harald Hofer

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Hepacivirus

Procedures

Concepts & Ideas

Physiology

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Harald Hofer; Peter Knoflach; Thomas Müller; Michael Trauner; Wolfgang Vogel; Claudia Willheim-Polli; Christian Gabriel; Peter Ferenci
Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study.
Albert Friedrich Stättermayer; Harald Hofer; Peter Ferenci
Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C.
Albert Friedrich Stättermayer; Petra Steindl-Munda; Michael Trauner; Fritz Wrba; Harald Hofer; Michael Krebs; Karoline Rutter; Thomas-Matthias Scherzer; Andreas Stadlmayr; Sandra Beinhardt; Christian Datz; Peter Ferenci
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Harald Hofer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Harald Hofer; Peter Knoflach; Thomas Müller; Michael Trauner; Wolfgang Vogel; Claudia Willheim-Polli; Christian Gabriel; Peter Ferenci
Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study.
Journal of human genetics 2012;57(9):564-7.
2012: Albert Friedrich Stättermayer; Harald Hofer; Peter Ferenci
Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C.
Journal of hepatology 2012;57(3):706; author reply 706-7.
2012: Albert Friedrich Stättermayer; Petra Steindl-Munda; Michael Trauner; Fritz Wrba; Harald Hofer; Michael Krebs; Karoline Rutter; Thomas-Matthias Scherzer; Andreas Stadlmayr; Sandra Beinhardt; Christian Datz; Peter Ferenci
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.
Journal of hepatology 2012;57(3):492-8.
2012: Michael Trauner; Anna Baghdasaryan; Peter Fickert; Emina Halilbasic; Harald Hofer; Elisabeth Krones; Tarek Moustafa; Edward Penner
Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment.
Digestive diseases (Basel, Switzerland) 2012;30 Suppl 1():39-47.
2011: Thomas-Matthias Scherzer; Albert Friedrich Stättermayer; Rudolf Stauber; Petra Steindl-Munda; Michael Strasser; Christian Datz; Emina Dulic-Lakovic; Harald Hofer; Hermann Laferl; Andreas Maieron; Peter Ferenci
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
Hepatology (Baltimore, Md.) 2011;54(5):1518-26.
2011: Thomas Reiberger; Karoline Rutter; Michael Trauner; Sandra Beinhardt; Peter Ferenci; Arnulf Ferlitsch; Alfred Gangl; Harald Hofer; Michael Kundi; Berit Anna Payer; Markus Peck-Radosavljevic
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(7):602-8.e1.
2011: Harald Hofer; C Mueller; S Neumueller-Guber; T-M Scherzer; K Staufer; Petra Steindl-Munda; F Wrba; I Aydin; Peter Ferenci
Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.
Journal of viral hepatitis 2011;18(7):513-7.
2011: Thomas-Matthias Scherzer; Harald Hofer; Albert Friedrich Staettermayer; Karoline Rutter; Sandra Beinhardt; Petra Steindl-Munda; Heidrun Kerschner; Harald H Kessler; Peter Ferenci
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
Journal of hepatology 2011;54(5):866-71.
2011: Albert Friedrich Stättermayer; Rudolf Stauber; Harald Hofer; Karoline Rutter; Sandra Beinhardt; Thomas Matthias Scherzer; Kerstin Zinober; Christian Datz; Andreas Maieron; Emina Dulic-Lakovic; Harald H Kessler; Petra Steindl-Munda; Michael Strasser; Christoph Krall; Peter Ferenci
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(4):344-350.e2.
2010: Harald Hofer; Josef Donnerer; Kathrin Sator; Katharina Staufer; Thomas-Matthias Scherzer; Clemens Dejaco; Michael Sator; Harald Kessler; Peter Ferenci
Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy.
Journal of hepatology 2010;52(6):812-6.
2010: Martin Krssák; Harald Hofer; Fritz Wrba; Martin Meyerspeer; Attila Brehm; Alfred Lohninger; Petra Steindl-Munda; Ewald Moser; Peter Ferenci; Michael Roden
Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy.
European journal of radiology 2010;74(3):e60-6.
2010: Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Andreas Maieron; Harald Hofer; Rudolf Stauber; Michael Gschwantler; Harald Brunner; Christoph Wenisch; Martin Bischof; Michael Strasser; Christian Datz; Wolfgang Vogel; Karin Löschenberger; Petra Steindl-Munda
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Gastroenterology 2010;138(2):503-12, 512.e1.
2008: Peter Ferenci; Thomas-Matthias Scherzer; Heidrun Kerschner; Karoline Rutter; Sandra Beinhardt; Harald Hofer; Maximilian Schöniger-Hekele; Heidemarie Holzmann; Petra Steindl-Munda
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
Gastroenterology 2008;135(5):1561-7.
2008: T M Scherzer; K Staufer; Gottfried Novacek; Petra Steindl-Munda; S Schumacher; Harald Hofer; Peter Ferenci; Harald Vogelsang
Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.
Alimentary pharmacology & therapeutics 2008;28(6):742-8.
2008: T-M Scherzer; K Rajender Reddy; F Wrba; Harald Hofer; K Staufer; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci
Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C.
Journal of viral hepatitis 2008;15(9):659-65.
2008: Peter Ferenci; Harald Brunner; Hermann Laferl; Thomas-Matthias Scherzer; Andreas Maieron; Michael Strasser; Gabriele Fischer; Harald Hofer; Martin Bischof; Rudolf E Stauber; Michael Gschwantler; Petra Steindl-Munda; Katharina Staufer; Karin Löschenberger
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Hepatology (Baltimore, Md.) 2008;47(6):1816-23.
2006: Harald Hofer; Calin Gurguta; Ulrike Bergholz; Petra Steindl-Munda; Peter Ferenci
Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
Wiener klinische Wochenschrift 2006;118(19-20):595-600.
2006: Harald Hofer; C Oesterreicher; Fritz Wrba; Peter Ferenci; Edward Penner
Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation.
Journal of clinical pathology 2006;59(3):246-9.
2006: Elisabeth Formann; Petra Steindl-Munda; Harald Hofer; Wolfgang Jessner; Ulrike Bergholz; Calin Gurguta; Peter Ferenci
Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
Alimentary pharmacology & therapeutics 2006;23(4):507-11.
2005: Ludwig Kramer; Harald Hofer; Edith Bauer; Georg Funk; Elisabeth Formann; Petra Steindl-Munda; Peter Ferenci
Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection.
AIDS (London, England) 2005;19 Suppl 3():S85-92.
2005: Christoph H Osterreicher; Christian Datz; Felix Stickel; Claus Hellerbrand; Melitta Penz; Harald Hofer; Fritz Wrba; Edward Penner; Detlef Schuppan; Peter Ferenci
TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis.
Cytokine 2005;31(2):142-8.
2005: Christoph H Osterreicher; Christian Datz; Felix Stickel; Claus Hellerbrand; Melitta Penz; Harald Hofer; Fritz Wrba; Edward Penner; Detlef Schuppan; Peter Ferenci
Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis.
Journal of hepatology 2005;42(6):914-9.
2005: Harald Hofer; J B Neufeld; C Oesterreicher; Paul Grundtner; Fritz Wrba; Alfred Gangl; Peter Ferenci; Christoph Gasche
Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection.
Genes and immunity 2005;6(3):242-7.
2004: Rudolf E Stauber; Harald Hofer; Franz Hackl; Kurt Schütze; Christian Datz; Karin Hegenbarth; Wolfgang Jessner; Petra Steindl-Munda; Ferenci Peter
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Wiener klinische Wochenschrift 2004;116(15-16):530-5.
2004: Harald Hofer; Christoph H Osterreicher; Wolfgang Jessner; Melitta Penz; Petra Steindl-Munda; Fritz Wrba; Peter Ferenci
Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Journal of hepatology 2004;40(6):1018-22.
2003: Petra Steindl-Munda; Peter Ferenci; Harald Brunner; Karin Nachbaur; Christian Datz; Michael Gschwantler; Harald Hofer; Rudolf E Stauber; Franz Hackl; Wolfgang Jessner; Martha Rosenbeiger; Alfred Gangl; Wolfgang Vogel
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Liver international : official journal of the International Association for the Study of the Liver 2003;23(4):269-75.
2003: Wolfgang Jessner; Rudolf E Stauber; Franz Hackl; Christian Datz; Thomas Watkins-Riedel; Harald Hofer; Alfred Gangl; H Kessler; Peter Ferenci
Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
Journal of viral hepatitis 2003;10(1):37-42.
2003: Harald Hofer; Thomas Watkins-Riedel; Oskar Janata; Edward Penner; Heidemarie Holzmann; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.
Hepatology (Baltimore, Md.) 2003;37(1):60-4.
2002: Harald Hofer; Hans C Bankl; Fritz Wrba; Petra Steindl-Munda; Markus Peck-Radosavljevic; Christoph H Osterreicher; Christian Mueller; Alfred Gangl; Peter Ferenci
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.
The American journal of gastroenterology 2002;97(11):2880-5.
2002: Ludwig Kramer; Edith Bauer; Georg Funk; Harald Hofer; Wolfgang Jessner; Petra Steindl-Munda; Fritz Wrba; Christian Madl; Alfred Gangl; Peter Ferenci
Subclinical impairment of brain function in chronic hepatitis C infection.
Journal of hepatology 2002;37(3):349-54.
2002: Markus Peck-Radosavljevic; Martina Wichlas; Monika Homoncik-Kraml; Anna Kreil; Harald Hofer; Wolfgang Jessner; Alfred Gangl; Peter Ferenci
Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.
Gastroenterology 2002;123(1):141-51.
2002: Petra Bareis; Enikö Kállay; Martin G Bischof; Giovanna Bises; Harald Hofer; Christian Pötzi; Teresa Manhardt; Rosemary Bland; Heide S Cross
Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
Experimental cell research 2002;276(2):320-7.
2001: Peter Ferenci; Harald Brunner; K Nachbaur; Christian Datz; Michael Gschwantler; Harald Hofer; Rudolf E Stauber; Franz Hackl; Wolfgang Jessner; M Rosenbeiger; P Munda-Steindl; Karin Hegenbarth; Alfred Gangl; Wolfgang Vogel
Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
Hepatology (Baltimore, Md.) 2001;34(5):1006-11.
2001: Heide S Cross; Petra Bareis; Harald Hofer; Martin G Bischof; Erika Bajna; Stephan Kriwanek; Elisabeth Bonner; Meinrad Peterlik
25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis.
Steroids 2001;66(3-5):287-92.
1999: Wei-Min Tong; Harald Hofer; Adolf Ellinger; Meinrad Peterlik; Heide S Cross
Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth.
Oncology research 1999;11(2):77-84.
1998: Wei-Min Tong; Enikö Kállay; Harald Hofer; Wolfgang Hulla; Teresa Manhardt; Meinrad Peterlik; Heide S Cross
Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression.
European journal of cancer (Oxford, England : 1990) 1998;34(13):2119-25.